Recent Developments in Targeted Therapies of the RAF-MEK and PI3K-AKT Pathways in Cancer Treatment

被引：0
作者：
Cremers, Lobke G. M. [1 ]
Boonstra, Johannes [1 ]
机构：
[1] Univ Utrecht, Cell Biol, Utrecht, Netherlands
来源：
CURRENT CANCER THERAPY REVIEWS | 2012年 / 8卷 / 03期
关键词：
AKT; Antitumor activity; Inhibitors; MEK; PI3K; RAF; Targeted drugs;
D O I：
10.2174/157339412802653209
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The RAF-MEK and PI3K-AKT pathways are both frequently deregulated in cancer, and often play a critical role in oncogenesis. In the previous years, major progress has been made in the development of targeted drugs against signaling kinases which are involved in carcinogenesis. Currently, targeted drugs against RAF, MEK, PI3K and AKT (among several others) have entered clinical investigation. Here we describe tumor causing mutations of these kinases, as well as the small molecule inhibitors that target these kinases, which contributes to improved ways of treating human cancer.
引用
收藏
页码：205 / 217
页数：13
相关论文
共 165 条
  • [1] Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
    Adjei, Alex A.
    Cohen, Roger B.
    Franklin, Wilbur
    Morris, Clive
    Wilson, David
    Molina, Julian R.
    Hanson, Lorelei J.
    Gore, Lia
    Chow, Laura
    Leong, Stephen
    Maloney, Lara
    Gordon, Gilad
    Simmons, Heidi
    Marlow, Allison
    Litwiler, Kevin
    Brown, Suzy
    Poch, Gregory
    Kane, Katie
    Haney, Jerry
    Eckhardt, S. Gail
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2139 - 2146
  • [2] IDENTIFICATION OF THE SITES IN MAP KINASE KINASE-1 PHOSPHORYLATED BY P74(RAF-1)
    ALESSI, DR
    SAITO, Y
    CAMPBELL, DG
    COHEN, P
    SITHANANDAM, G
    RAPP, U
    ASHWORTH, A
    MARSHALL, CJ
    COWLEY, S
    [J]. EMBO JOURNAL, 1994, 13 (07) : 1610 - 1619
  • [3] 3-phosphoinositide-dependent protein kinase-1 (PDK1): structural and functional homology with the Drosophila DSTPK61 kinase
    Alessi, DR
    Deak, M
    Casamayor, A
    Caudwell, FB
    Morrice, N
    Norman, DG
    Gaffney, P
    Reese, CB
    MacDougall, CN
    Harbison, D
    Ashworth, A
    Bownes, M
    [J]. CURRENT BIOLOGY, 1997, 7 (10) : 776 - 789
  • [4] Arboleda MJ, 2003, CANCER RES, V63, P196
  • [5] AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K
    Askham, J. M.
    Platt, F.
    Chambers, P. A.
    Snowden, H.
    Taylor, C. F.
    Knowles, M. A.
    [J]. ONCOGENE, 2010, 29 (01) : 150 - 155
  • [6] Isoform-specific regulation of insulin-dependent glucose uptake by Akt/protein kinase B
    Bae, SS
    Cho, H
    Mu, J
    Birnbaum, MJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (49) : 49530 - 49536
  • [7] Baselga J, 2010, J CLIN ONCOL
  • [8] Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents
    Bellmunt, Joaquim
    Montagut, Clara
    Albiol, Santiago
    Carles, Joan
    Maroto, Pablo
    Orsola, Anna
    [J]. BJU INTERNATIONAL, 2007, 99 (02) : 274 - 280
  • [9] Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer
    Blumenschein, George R., Jr.
    Gatzemeier, Ulrich
    Fossella, Frank
    Stewart, David J.
    Cupit, Lisa
    Cihon, Frank
    O'Leary, James
    Reck, Martin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : 4274 - 4280
  • [10] Boonstra J, 2005, CRIT REV EUKAR GENE, V15, P255
12345678910